TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00391768
Drug: oseltamivir (Tamiflu®)
Normalized name: oseltamivir Oral Suspension [Tamiflu]
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
Study: NCT02462590
Drug: Placebo - Microcrystalline Cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline Cellulose
Study: NCT04444011
Drug: Anaprazole Sodium
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaprazole Sodium isthePPI inhibitor
Study: NCT04444011
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic
Study: NCT04444011
Drug: Bismuth
Normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth is to protect the gastric mucosa
Study: NCT04598061
Drug: Dexmedetomidine IV
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine IV
Study: NCT05682209
Drug: Octreotide Injection
Normalized name: octreotide Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
Study: NCT02745431
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00117273
Drug: Seasonique (LNG/EE and EE)
Normalized name: norgestimate
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet daily
Study: NCT00117273
Drug: Portia (LNG/EE)
Normalized name: ethinyl estradiol
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet daily x 28 days
Study: NCT00406367
Drug: incobotulinumtoxinA (Xeomin)
Normalized name: incobotulinumtoxinA Injection [Xeomin]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection
Study: NCT04022057
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic injection
Study: NCT04483830
Drug: Sulodexide
Normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an oral dose of 2 capsules each day for 21 days
Study: NCT01412567
Drug: Vaccine+HBIG
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
Study: NCT01762644
Drug: Oral Cyclosporine and Oral Omeprazole
Normalized name: cyclosporine Oral Capsule
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01762644
Drug: Oral Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01568892
Drug: Dolutegravir 50 mg twice daily
Normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
Study: NCT01568892
Drug: Dolutegravir placebo twice daily
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
Study: NCT01275365
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 100 mg intramuscularly weekly
Study: NCT01567774
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: os, 20 mg, once per day, for 30 days
Study: NCT00863655
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Study: NCT02199431
Drug: Lu AF11167
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02199431
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02962492
Drug: Exenatide/Exenatide extended release
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
Study: NCT02962492
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
Study: NCT02825017
Drug: Coppertone (BAY 987517)
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm\*2 test application.(Formulation-SR15-79_Y73-161)
Study: NCT00292734
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03150719
Drug: Tezacaftor/Ivacaftor
Normalized name: ELEXACAFTOR/TEZACAFTOR/IVACAFTOR 100-50-75MG/75MG PKT,14
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
Study: NCT03150719
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IVA 150 mg tablet.
Study: NCT00863655
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 25 mg orally daily.
Study: NCT00384618
Drug: vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03212638
Drug: Baricitinib tablet
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT00450099
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
Study: NCT04087993
Drug: Polyglucoferron
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT04087993
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous administration
Study: NCT04087993
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT03657420
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
Study: NCT03657420
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is a steroid which is believed to kill cancer cells
Study: NCT00249301
Drug: MLN8054
Normalized name: MLN8054
DrugBank: MLN8054 (DB13061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
Study: NCT00863655
Drug: Everolimus Placebo
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Study: NCT00869622
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mgs/week + calcium and vit d
Study: NCT01894386
Drug: FF 400 mcg
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
Study: NCT01894386
Drug: UMEC 500 mcg
Normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 125 mcg powder for inhalation delivered by DPI
Study: NCT01894386
Drug: UMEC 250 mcg
Normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 62.5 mcg powder for inhalation delivered by DPI
Study: NCT01894386
Drug: VI 100 mcg
Normalized name: azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mcg powder for inhalation delivered by DPI
Study: NCT00000122
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02770794
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Discontinue infliximab; receive Infliximab when relapse
Study: NCT01703572
Drug: OMP-52M51
Normalized name: OMP-52M51
DrugBank: Brontictuzumab (DB12737)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04735523
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dispensing claim is used as the exposure group
Study: NCT04735523
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin dispensing claim is used as the reference group
Study: NCT03403140
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week
Study: NCT01051791
Drug: Everolimus 10mg daily
Normalized name: everolimus 10 MG
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
Study: NCT00802230
Drug: Terbutaline Infusion
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03498430
Drug: Copanlisib (Aliqopa, BAY80-6946)
Normalized name: copanlisib Injection [Aliqopa]
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
Study: NCT01107522
Drug: CTO
Normalized name: Actos
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
Study: NCT03074825
Drug: Chiauranib
Normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 50mg orally once daily
Study: NCT04494503
Drug: APG-2575
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-2575 orally once daily, every 28 days as a cycle.
Study: NCT04494503
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
Study: NCT04494503
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
Study: NCT03825796
Drug: Enasidenib Mesylate
Normalized name: Enasidenib Mesylate
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03825796
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03809663
Drug: Tezepelumab
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT02183324
Drug: Medium dose of BI 1356 BS
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183324
Drug: High dose of BI 1356 BS
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01051596
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150mg/m2 Days 1-5 of each 28 day cycle
Study: NCT01051596
Drug: ABT-888
Normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg orally BID Days 1-7 of each 28 day cycle
Study: NCT00216580
Drug: Risperidone, long-acting injectable
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01285362
Drug: Fish Oil Supplementation
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
Study: NCT01707394
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04633967
Drug: Alemtuzumab Injection
Normalized name: alemtuzumab Injection
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol~Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.~Premedication with 50 mg of prednisone orally for 5 days before the infusion.~During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.~Post Infusion Medication~Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.~Post-medication with 50 mg of prednisone orally for 5 days after the infusion.~Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed
Study: NCT00175123
Drug: Botulinum A toxin
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intravesical injection. 12 IE/kg b.w.
Study: NCT04479436
Drug: Patritumab Deruxtecan
Normalized name: patritumab deruxtecan
DrugBank: Patritumab (DB12090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
Study: NCT00751062
Drug: timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Study: NCT04570839
Drug: COM701 in combination with BMS-986207 and nivolumab.
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
Study: NCT03004638
Drug: MEDI6012 40 mg
Normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
Study: NCT03004638
Drug: MEDI6012 120 mg
Normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
Study: NCT03004638
Drug: MEDI6012 300 mg
Normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
Study: NCT03004638
Drug: MEDI6012 IV Push
Normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
Study: NCT02418949
Drug: Cyproheptadine
Normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug
Study: NCT02418949
Drug: Placebo for Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug
Study: NCT01139775
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously as a continuous 10-minute infusion
Study: NCT01139775
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously as a continuous 1-hour infusion
Study: NCT03146806
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse.
Study: NCT03238560
Drug: Montelukast Chewable Tablet
Normalized name: montelukast Chewable Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast treatment was used at a dosage of 5mg/day once daily
Study: NCT00758290
Drug: Triclosan/Fluoride
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily for 3 weeks
Study: NCT00758290
Drug: Fluoride/triclosan
Normalized name: Sodium Fluoride/Triclosan Topical application Paste
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush daily for 3 weeks
Study: NCT04733066
Drug: Teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intervention group consists of patients, who receive teduglutide within routine medical care
Study: NCT01131169
Drug: busulfan, melphalan and fludarabine
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
Study: NCT00014495
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02707484
Drug: Thalidomide (100mg)
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
Study: NCT02707484
Drug: Thalidomide (50mg)
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
Study: NCT01882985
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV